Engineering a longer dosing interval
PepTetris combines AI-guided design, molecular engineering and half-life extension with activity at multiple targets. The work balances persistence in the body with potency, manufacturing requirements and the properties needed for clinical development.
Taking the lead candidate toward human testing
TPM004 is being advanced toward an investigational drug filing and Phase I trials. Monthly subcutaneous dosing remains a development goal supported by preclinical work. The company was incubated by Shenzhen Bay Laboratory and plans key clinical data in 2027.
Where the funding goes
- TPM004 investigational drug filing
- Phase I clinical development
- PepTetris platform and early pipelines